Table 4 Multivariable Linear Regression Analysis for the CAP Progression Rate.
Model 1 (Clinical RFs + BACS) | Model 2 (Clinical RFs + CACS + BACS) | Model 3 (Clinical RFs + Segment stenosis score + BACS) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
β | 95% CI | t | P | β | 95% CI | t | p | β | 95% CI | t | p | |
Age, years | 0.002 | −0.003–0.007 | 0.916 | 0.362 | 0.002 | −0.003–0.007 | 0.779 | 0.438 | 0.002 | −0.003–0.007 | 0.775 | 0.440 |
Number of parity | 0.004 | −0.023–0.030 | 0.291 | 0.772 | 0.003 | −0.024–0.030 | 0.207 | 0.836 | 0.004 | −0.023–0.030 | 0.266 | 0.791 |
Hypertension, n (%) | −0.026 | −0.095–0.043 | −0.746 | 0.457 | −0.027 | −0.096–0.042 | −0.769 | 0.444 | −0.025 | −0.094–0.045 | −0.704 | 0.483 |
Current smoking, n (%) | 0.073 | −0.128–0.274 | 0.721 | 0.472 | 0.072 | −0.130–0.273 | 0.705 | 0.483 | 0.076 | −0.126–0.277 | 0.745 | 0.458 |
Systolic blood pressure, mmHg | 0.001 | 0.000–0.003 | 1.793 | 0.076 | 0.001 | 0.000–0.003 | 1.818 | 0.072 | 0.001 | 0.000–0.003 | 1.620 | 0.108 |
Serum creatinine, mg/dL | 0.122 | −0.193–0.437 | 0.767 | 0.445 | 0.134 | −0.185–0.452 | 0.834 | 0.406 | 0.104 | −0.216–0.423 | 0.644 | 0.521 |
HbA1c, % | 0.031 | −0.002––0.063 | 1.840 | 0.069 | 0.031 | −0.002–0.064 | 1.851 | 0.067 | 0.028 | −0.006–0.062 | 1.651 | 0.102 |
High-density lipoprotein, mg/dL | 0.000 | −0.002–0.002 | 0.126 | 0.900 | 0.000 | −0.002–0.002 | 0.189 | 0.851 | 0.000 | −0.002–0.002 | 0.172 | 0.864 |
Low-density lipoprotein, mg/dL | 0.000 | −0.001–0.001 | 0.378 | 0.706 | 0.000 | −0.001–0.001 | 0.319 | 0.750 | 0.000 | −0.001–0.001 | 0.332 | 0.741 |
Statin therapy after CCTA | −0.023 | −0.105–0.059 | −0.560 | 0.577 | −0.025 | −0.107–0.057 | −0.606 | 0.546 | −0.029 | −0.113–0.054 | −0.693 | 0.490 |
CACS | 0.000 | 0.000–0.001 | 0.645 | 0.520 | ||||||||
SSS | 0.010 | −0.016–0.035 | 0.762 | 0.448 | ||||||||
BACS | 0.020 | 0.005–0.035 | 2.629 | 0.010 | 0.019 | 0.004–0.034 | 2.556 | 0.012 | 0.019 | 0.004–0.035 | 2.577 | 0.011 |
